NEW YORK (GenomeWeb News) — Quest Diagnostics has licensed from Pathway Diagnostics the underlying technology used in its co-receptor tropism HIV assay, Quest said today.
The non-exclusive license covers the heteroduplex tracking technology used in Pathway’s SensiTrop test. Quest said that a molecular-based assay for co-receptor tropism will help physicians personalize HIV therapy.
Quest, which is the first full-service national clinical laboratory in the US to license the technology, expects to develop a validated assay using the technology in the first quarter of 2008. Until then, the SensiTrop test may be ordered through Quest, which will refer the test to Pathway Diagnostics.
"HIV co-receptor tropism tests can help physicians identify which patients, of the estimated 500,000 people in the US being treated for HIV infection, will benefit from entry inhibitor drugs, the latest development in life-enhancing anti-retroviral therapies,” Joyce Schwartz, Quest’s vice president and chief laboratory officer, said in a statement.
Financial terms of the agreement were not released.